Key statistics
On Friday, Syndax Pharmaceuticals Inc (SNDX:NSQ) closed at 9.59, 11.77% above the 52 week low of 8.58 set on May 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.74 |
---|---|
High | 9.82 |
Low | 9.48 |
Bid | 9.49 |
Offer | 9.59 |
Previous close | 9.82 |
Average volume | 2.00m |
---|---|
Shares outstanding | 86.05m |
Free float | 83.79m |
P/E (TTM) | -- |
Market cap | 825.20m USD |
EPS (TTM) | -3.86 USD |
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
- Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
- Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Syndax Announces Participation in June Investor Conferences
- Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
- Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
- Syndax Announces Participation in May Investor Conferences
- Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
More ▼